Version June 2024
| Recommended US Food and Drug Administration testing guidelines per American Society of Reproductive Medicine for donors in a gestational carrier (GC) cycle and options for protecting the GC from infection: | |
| Male and female partners: | Test |
| 1 | HIV-1 antibody and nucleic acid testing (NAT) |
| 2 | HIV-2 antibody |
| 3 | HIV group O antibody. If US FDA-licensed test for HIV group O antibodies is unavailable then evaluation for genetic parents for risk associated with HIV group O infection |
| 4 | Hepatitis C antibody and NAT |
| 5 | Hepatitis B surface antigen |
| 6 | Hepatitis B core antibody (IgG and IgM) |
| 7 | Serologic test for syphilis |
| 8 | Neisseria gonorrhoeae and Chlamydia trachomatis NAT on urine or swab from cervix, urethral meatus or vagina |
| 9 | Rh compatibility with the gestational carrier and appropriate counseling |
| Additional testing for male partner: | |
| 1 | Human T-lymphotropic virus I (HTLV-I) and human T-lymphotropic virus II (HTLV-II) |
| 2 | Cytomegalovirus (CMV) (IgG and IgM) |
| Any positive test results need to be responded to per standard Centers for Disease Control and Prevention guidelines and GCs offered the option of cryopreservation of embryos for 180 days until such test results are resolved and donors are retested. | |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
